Recordati : Q1 results: a solid operational performance and guidance reiterated
>Slightly higher profitability than expected - Recordati has published its Q1 results. Sales, already announced, were up 10.9% cc to € 608m driven by the momentum of the SPC (+10.1% cc at € 395.5m) and rare diseases franchises (+13.9% cc at € 197.5m) reabsorbing the negative forex of -5.7% notably due to the depreciation of the Turkish lira. On the operational front, profitability was slightly better than expected with an EBITDA margin at 40.2% of sales (vs co...Recordati-Industria Chimica e Farmaceutica is a pharmaceutical group based in Italy. Co.'s operations are divided into two operating segments: pharmaceuticals (and pharmaceutical chemicals) and orphan drugs. Co.'s products include ZANIPRESS®/ZANEXTRA®/LERCAPREL®/LERCARIL®, an antihypertensive drug; ZANIDIP®/CORIFEO®/LERCADIP® (lercanidipine), an antihypertensive drug discovered and developed in Co.'s research laboratories; UROREC® (silodosin), a new drug indicated for the treatment of benign prostatic hyperplasia; and LIVAZO®/ALIPZA® (pitavastatin), a statin for the treatment of dyslipidemia, among others.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.